Manzoor Ahmad Mir – författare

Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation.

The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases.

Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases

Considering the global emerging human pathogenic microbial diseases and trends, Human Pathogenic Microbes is framed to provide deep insights into the epidemic and emerging bacterial and fungal infections and diseases in humans. It presents novel, up-to-date, and cutting-edge knowledge regarding various human pathogenic microbes, their associated drug resistance mechanisms, and different diseases caused by them.

Human Pathogenic Microbes reflects the current research and development on the evolution of bacterial and fungal drug resistance: different bacterial and fungal antimicrobial drug resistance mechanisms along with their biological and molecular aspects.

In a nutshell, Human Pathogenic Microbes describes a various bacterial and fungal diseases caused by different human pathogenic microbes employing different drug resistance mechanisms and processes. It also highlights the novel emerging approaches (Immunological and combinatorial) that will aid to fight against such bacterial and fungal pathogens.

Provides a brief but thorough and recent knowledge of various human pathogenic microbes, their associated drug resistance mechanisms, and different diseases caused by them Describes the different aspects of fungal, bacterial and antimicrobial resistance Addresses novel antimicrobial agents and approaches

Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance. Combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making it essential to understand for multiple therapy options.

The book is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer.

Presents up-to-date and cutting-edge knowledge of Triple negative breast cancer (TNBC) biology, clinical aspects and treatment options Discusses novel targets and pathways involved in TNBC Provides insights and approaches for future research on TNBC

Role of Tumor Microenvironment in Breast Cancer and Targeted Therapies discusses the current understanding of breast cancer tumor microenvironment components, their role in tumorigenicity and the development of therapeutic resistance, along with updates on recent advances. Presents up-to-date knowledge on the interplays of stromal components surrounding breast tumor cells Explores recent advances and trends in the molecular mechanisms of breast tumorigenesis and how to explore further molecular targets

Genetic Testing in Breast Cancer: Innovations in Diagnosis and Treatment addresses the urgent need for novel, minimally invasive diagnostic techniques to accurately identify breast cancer early and monitor treatment efficacy, focusing particularly on triple-negative breast cancer (TNBC). This comprehensive volume analyzes the latest research and developments in genetic testing, covering strategies like next-generation sequencing and the Sanger method. It highlights their potential to revolutionize early diagnosis and personalized treatment plans. The book also discusses challenges and opportunities, providing insights into hereditary mutations, genetic counseling, and clinical practice integration.Serving as a valuable resource for students, researchers, oncologists, pharmacologists, and healthcare professionals, it includes preclinical and clinical case studies that illustrate the practical applications of genetic testing for various breast cancer subtypes, including TNBC and HER2-positive breast cancer. The editors aim to advance treatment and improve patient outcomes through cutting-edge genetic testing techniques.Explores the latest genetic testing strategies, including next-generation sequencing and the Sanger method for early and accurate breast cancer diagnosis and treatmentIncludes practical preclinical and clinical case studies that demonstrate the application of genetic testing for various breast cancer subtypes, such as TNBC and HER2-positive breast cancerProvides in-depth insights into the challenges and opportunities in integrating genetic testing into clinical practice, with a focus on personalized treatment plans

Retinoids as Anti-cancer Agents in Breast Cancer: A New Hope for Breast Cancer Treatment offers a comprehensive overview of the latest research and advancements in using retinoids to treat breast cancer. The book delves into novel approaches, including drug combinations and the development of new pharmaceuticals. It provides an in-depth analysis of current treatment methods, highlighting both challenges and opportunities in the field. Topics covered include the principles and mechanisms of retinoids as anti-cancer agents, preclinical and clinical studies, and advancements in drug delivery systems and nano-formulations.Future research directions are also explored, emphasizing new drug combinations, biomarkers for patient selection, and personalized treatment strategies. This book will serve as a platform for students, researchers, oncologists, pharmacologists, and healthcare professionals who want to understand the potential of retinoids in clinical practice.Provides insights into the need for using cutting-else technology to develop novel pharmaceutical agents based on bioactive natural compounds for the efficient cancer treatment of breast cancerCaptures new research and knowledge to fully understand and potentially optimize the use of retinoids in breast cancer treatmentEvaluates the potential of retinoids in breast cancer treatment as novel alternatives to mainstream breast cancer therapy

AI in Breast Cancer Stem Cells and Proteomics: Precision Oncology Perspectives explores the intersection of artificial intelligence, cancer stem cell biology, and proteomics to address the persistent challenges of relapse, metastasis, and therapy resistance in breast cancer. This book provides a translational framework for precision oncology through advanced computational and molecular approaches. It gives insight into the biology of breast cancer stem cells (BCSCs), their heterogeneity, and the role of proteomics in identifying biomarkers and therapeutic targets. The integration of AI enables predictive modeling, drug resistance profiling, and multi-omics data analysis, offering novel insights into personalized treatment strategies. Academics benefit from a comprehensive, interdisciplinary resource that bridges cancer biology, bioinformatics, and clinical applications.The book equips researchers, clinicians, and students with case studies, algorithmic tools, and practical workflows to translate proteomic data into actionable medical interventions.Provides AI-driven frameworks for analyzing proteomic data in breast cancer stem cellsExplores post-translational modifications and protein-protein interactions as therapeutic targetsOffers interdisciplinary case studies linking computational biology with clinical oncology

This book provides the latest research and developments in the field of metronomic chemotherapy for breast cancer. It presents the principles and mechanisms of metronomic chemotherapy, preclinical and clinical studies, and the latest developments in drug delivery systems and nanoformulations. The clinical pharmacology of metronomic chemotherapy, including pharmacokinetics, pharmacogenetics, pharmacoeconomics, and adverse drug reactions, are also examined.Key Features:Introduces metronomics therapy in the neoadjuvant and adjuvant treatment of breast cancerExplores the potential of metronomics in terms of personalized chemotherapyPresent pharmacological bases of metronomic chemotherapyCovers the latest developments in drug delivery systems, nanotechnology, and nanoformulationsDiscusses antiangiogenic effects and the impact of metronomics on immunityThis book is useful for students, researchers, oncologists, pharmacologists, and healthcare experts interested in understanding the clinical potential of metronomic chemotherapy in breast cancer.

p53 in Breast Cancer: Molecular Mechanisms, Clinical Implications, and Therapeutic Targets comprehensively reviews the role of p53 in breast cancer development, progression, and treatment. It explores the multifaceted functions of p53, from its fundamental connection to breast cancer and pathway mechanisms to its influence on cancer metabolism and the impact of mutational alterations. The initial chapters discuss the complex landscape of p53's involvement in cancer metabolism, the ramifications of its mutations, and its crucial role as a tumor suppressor. The subsequent chapters review the regulatory functions of p53 in cell death, DNA repair, genomic stability, and cell cycle dynamics, highlighting its interactions with transcription factors, DNA repair enzymes, and family members p63 and p73. It further reviews the regulation of mutant p53 via post-translational modifications and delves into the approaches to combat mutated p53, highlighting targeted therapies and efforts to overcome chemoresistance. The chapters also address the role of p53 biomarkers in diagnosis and prognosis, the optimization of treatment responses, and the impact of nutrition on p53 activity. This book is an important resource for oncology and molecular biology researchers. Key FeaturesProvides a thorough examination of the p53 gene and its crucial involvement in breast cancer.Explores the critical implications of mutational alterations in p53 on the development and progression of breast cancer.Examines the role of p53 in managing apoptosis and contributing to DNA repair and genomic stability.Discusses the complex interactions of p53 with transcription factors, DNA repair enzymes, p63, and p73.Highlights the role of p53 as a biomarker in diagnosing and predicting breast cancer prognosis.

Cytokine and Chemokine Networks in Cancer" provides a comprehensive exploration of the roles of cytokines and chemokines in cancer biology. It describes the complex networks mediated by cytokine and chemokine receptors promoting tumor cell proliferation, site-directed metastasis, and activation of angiogenic switch in tumor cells.